193 related articles for article (PubMed ID: 33428503)
21. Epithelial-mesenchymal transition: When tumor cells meet myeloid-derived suppressor cells.
Cai J; Cui Y; Yang J; Wang S
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188564. PubMed ID: 33974950
[TBL] [Abstract][Full Text] [Related]
22. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
[TBL] [Abstract][Full Text] [Related]
23. Tolerability and Efficacy of Bevacizumab Monotherapy in Older Patients With Recurrent Ovarian Cancer.
Shintani D; Yoshida H; Yabuno A; Fujiwara K
In Vivo; 2020; 34(3):1451-1457. PubMed ID: 32354945
[TBL] [Abstract][Full Text] [Related]
24. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
Jiang Y; Zhan H
Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
[TBL] [Abstract][Full Text] [Related]
25. Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors.
Bronte G; Verlicchi A; De Matteis S; Rossi A; Affatato A; Sullo FG; Gianni C; Canale M; Burgio MA; Delmonte A; Milella M; Crinò L
Front Immunol; 2021; 12():672219. PubMed ID: 34122429
[TBL] [Abstract][Full Text] [Related]
26. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
27. RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells.
Soong RS; Anchoori RK; Yang B; Yang A; Tseng SH; He L; Tsai YC; Roden RB; Hung CF
Oncotarget; 2016 Oct; 7(42):68489-68502. PubMed ID: 27655678
[TBL] [Abstract][Full Text] [Related]
28. Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies.
Shou D; Wen L; Song Z; Yin J; Sun Q; Gong W
Oncotarget; 2016 Sep; 7(39):64505-64511. PubMed ID: 27542274
[TBL] [Abstract][Full Text] [Related]
29. Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF.
Di Tacchio M; Macas J; Weissenberger J; Sommer K; Bähr O; Steinbach JP; Senft C; Seifert V; Glas M; Herrlinger U; Krex D; Meinhardt M; Weyerbrock A; Timmer M; Goldbrunner R; Deckert M; Scheel AH; Büttner R; Grauer OM; Schittenhelm J; Tabatabai G; Harter PN; Günther S; Devraj K; Plate KH; Reiss Y
Cancer Immunol Res; 2019 Dec; 7(12):1910-1927. PubMed ID: 31597643
[TBL] [Abstract][Full Text] [Related]
30. Netrin-1 blockade inhibits tumor associated Myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitor.
Ducarouge B; Redavid AR; Victoor C; Chira R; Fonseca A; Hervieu M; Bergé R; Lengrand J; Vieugué P; Neves D; Goddard I; Richaud M; Laval PA; Rama N; Goldschneider D; Paradisi A; Gourdin N; Chabaud S; Treilleux I; Gadot N; Ray-Coquard I; Depil S; Decaudin D; Némati F; Marangoni E; Mery-Lamarche E; Génestie C; Tabone-Eglinger S; Devouassoux-Shisheboran M; Moore KJ; Gibert B; Mehlen P; Bernet A
Cell Death Differ; 2023 Oct; 30(10):2201-2212. PubMed ID: 37633969
[TBL] [Abstract][Full Text] [Related]
31. Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles.
Wei Z; Zhang X; Yong T; Bie N; Zhan G; Li X; Liang Q; Li J; Yu J; Huang G; Yan Y; Zhang Z; Zhang B; Gan L; Huang B; Yang X
Nat Commun; 2021 Jan; 12(1):440. PubMed ID: 33469052
[TBL] [Abstract][Full Text] [Related]
32. Combinations of Bevacizumab With Cancer Immunotherapy.
Chen DS; Hurwitz H
Cancer J; 2018; 24(4):193-204. PubMed ID: 30119083
[TBL] [Abstract][Full Text] [Related]
33. A Call for Epidemiological Research on Myeloid-Derived Suppressor Cells in Ovarian Cancer: A Review of the Existing Immunological Evidence and Suggestions for Moving Forward.
Stenzel AE; Abrams SI; Moysich KB
Front Immunol; 2019; 10():1608. PubMed ID: 31354741
[TBL] [Abstract][Full Text] [Related]
34. Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic.
Gao F; Yang C
Curr Cancer Drug Targets; 2020; 20(1):3-18. PubMed ID: 31729943
[TBL] [Abstract][Full Text] [Related]
35. Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells.
Vito A; Salem O; El-Sayes N; MacFawn IP; Portillo AL; Milne K; Harrington D; Ashkar AA; Wan Y; Workenhe ST; Nelson BH; Bruno TC; Mossman KL
Commun Biol; 2021 Jul; 4(1):859. PubMed ID: 34253827
[TBL] [Abstract][Full Text] [Related]
36. Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment.
Darragh LB; Oweida AJ; Karam SD
Front Immunol; 2018; 9():3154. PubMed ID: 30766539
[TBL] [Abstract][Full Text] [Related]
37. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
Kwa MJ; Adams S
Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
[TBL] [Abstract][Full Text] [Related]
38. Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors.
Sun J; Zheng Y; Mamun M; Li X; Chen X; Gao Y
Biomed Pharmacother; 2020 Sep; 129():110504. PubMed ID: 32768978
[TBL] [Abstract][Full Text] [Related]
39. Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma.
Mao Y; Eissler N; Blanc KL; Johnsen JI; Kogner P; Kiessling R
Clin Cancer Res; 2016 Aug; 22(15):3849-59. PubMed ID: 26957560
[TBL] [Abstract][Full Text] [Related]
40. Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model.
Zhu X; Xu J; Cai H; Lang J
J Obstet Gynaecol Res; 2018 Feb; 44(2):303-311. PubMed ID: 29171115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]